← FDA DRUG APPROVALS

FDA ANDA · ANDA205074

ZOLMITRIPTAN

Sponsor: ALEMBIC

APPLICATION
ANDA205074
TYPE
ANDA
ORIGINAL APPROVAL
2016-12-01
LATEST ACTION
2020-01-27
ROUTE
ORAL
DOSAGE FORM
TABLET, ORALLY DISINTEGRATING
MARKETING STATUS
Prescription

Products

ZOLMITRIPTANPrescription
ZOLMITRIPTAN 5MG · TABLET, ORALLY DISINTEGRATING · ORAL
ZOLMITRIPTANPrescription
ZOLMITRIPTAN 2.5MG · TABLET, ORALLY DISINTEGRATING · ORAL

Approval history

2020-01-27Labeling · Supplement 5 · standardAP
2016-12-01UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →